BidaskClub lowered shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a buy rating to a hold rating in a research note published on Wednesday morning, BidAskClub reports.
Several other brokerages have also commented on LXRX. Wedbush restated a buy rating and set a $17.00 price target on shares of Lexicon Pharmaceuticals in a research note on Wednesday, November 13th. Gabelli upgraded shares of Lexicon Pharmaceuticals from a hold rating to a buy rating and set a $3.00 price target on the stock in a research note on Wednesday, September 11th. Citigroup lowered shares of Lexicon Pharmaceuticals from a buy rating to a neutral rating and increased their price target for the stock from $3.00 to $4.00 in a research note on Friday, November 8th. G.Research upgraded shares of Lexicon Pharmaceuticals from a hold rating to a buy rating in a research note on Wednesday, September 11th. Finally, Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, November 16th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $6.45.
Lexicon Pharmaceuticals stock opened at $3.53 on Wednesday. The firm has a market cap of $373.01 million, a PE ratio of 2.58 and a beta of 0.95. The company has a debt-to-equity ratio of 1.42, a quick ratio of 8.01 and a current ratio of 8.11. The firm’s 50 day moving average price is $3.62 and its two-hundred day moving average price is $3.95. Lexicon Pharmaceuticals has a twelve month low of $1.13 and a twelve month high of $8.40.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.31 by $0.80. Lexicon Pharmaceuticals had a net margin of 49.78% and a return on equity of 2,372.40%. The company had revenue of $294.45 million for the quarter, compared to analyst estimates of $12.00 million. During the same quarter in the prior year, the business posted ($0.26) EPS. Lexicon Pharmaceuticals’s quarterly revenue was up 4124.5% on a year-over-year basis. Equities analysts anticipate that Lexicon Pharmaceuticals will post 0.93 EPS for the current fiscal year.
In other news, Director Christopher J. Sobecki bought 25,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were acquired at an average cost of $2.55 per share, for a total transaction of $63,750.00. Following the purchase, the director now owns 112,493 shares of the company’s stock, valued at approximately $286,857.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Lonnel Coats bought 50,000 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was purchased at an average price of $3.13 per share, for a total transaction of $156,500.00. Following the completion of the purchase, the chief executive officer now directly owns 127,639 shares in the company, valued at approximately $399,510.07. The disclosure for this purchase can be found here. Insiders purchased a total of 178,749 shares of company stock worth $474,560 over the last quarter. 6.40% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the stock. GSA Capital Partners LLP grew its stake in Lexicon Pharmaceuticals by 217.5% in the 2nd quarter. GSA Capital Partners LLP now owns 87,132 shares of the biopharmaceutical company’s stock valued at $548,000 after buying an additional 59,685 shares during the last quarter. Vanguard Group Inc. grew its stake in Lexicon Pharmaceuticals by 8.1% in the 2nd quarter. Vanguard Group Inc. now owns 4,240,111 shares of the biopharmaceutical company’s stock valued at $26,670,000 after buying an additional 319,382 shares during the last quarter. Morgan Stanley boosted its holdings in Lexicon Pharmaceuticals by 158.0% in the 2nd quarter. Morgan Stanley now owns 195,307 shares of the biopharmaceutical company’s stock valued at $1,229,000 after purchasing an additional 119,611 shares during the period. Wedbush Securities Inc. boosted its holdings in Lexicon Pharmaceuticals by 33.0% in the 2nd quarter. Wedbush Securities Inc. now owns 194,339 shares of the biopharmaceutical company’s stock valued at $1,222,000 after purchasing an additional 48,182 shares during the period. Finally, Pictet Asset Management Ltd. boosted its holdings in Lexicon Pharmaceuticals by 13.4% in the 2nd quarter. Pictet Asset Management Ltd. now owns 665,776 shares of the biopharmaceutical company’s stock valued at $4,188,000 after purchasing an additional 78,926 shares during the period. Institutional investors and hedge funds own 96.27% of the company’s stock.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Recommended Story: What causes a stock to be most active?
Receive News & Ratings for Lexicon Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
